Interleukin-2 gene therapy (VCL-IM01)

N/A

Report date: 2024/09/26 15:34:04

Base Information

Drug NameInterleukin-2 gene therapy (VCL-IM01)
Drug Alias NameInterleukin-2 gene therapy - VicalIL-2 plasmid DNA/lipid complex (Leuvectin)Electroporation-delivered DNA immunotherapy against metastatic melanoma - Inovio/VicalIL-2/EP - VicalLeuvectin +[7] 
ClassificationCell and gene therapy > Gene therapy > Plasmid
Mechanisms of ActionImmunostimulantsInterleukin-2 receptor agonistsGene transference
TargetsInterleukin-2 receptor
Therapy Area/IndicationsProstatic NeoplasmsMelanoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesInovio Pharmaceuticals IncFresh Tracks Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesVical Incorporated
Active IndicationsN/A
Inactive IndicationsProstatic NeoplasmsMelanoma

Other Information

ATC CodeN/A
Related LinksN/A